A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway

Table 4 Multivariable Cox regression analysis of disease specific survival

Variable	Hazards ratio (95% CI)	P value
Colon and rectal samples (N = 214)
Age (< 60 vs. ≥ 60)	1.476 (1.085–2.008)	0.013
Stage (I/II vs. III)	1.007 (0.657–1.544)	0.974
Stage (I/II vs. IV)	1.862 (1.295–2.677)	0.001
Neoadjuvant treatment (no vs. yes)	1.212 (0.879–1.673)	0.241
SEPT9 methylation (non-Hyper. vs. hypermethylated)	0.673 (0.469–0.965)	0.031
Colon samples (N = 110)
Age (< 60 vs. >=60)	1.730 (1.079–2.773)	0.023
Stage (I/II vs. III)	0.966 (0.486–1.922)	0.922
Stage (I/II vs. IV)	1.454 (0.859–2.463)	0.164
Neoadjuvant treatment (no vs. yes)	1.237 (0.677–2.259)	0.490
Tumor location (distal vs. proximal)	1.879 (1.174–3.007)	0.009
SEPT9 methylation (non-Hyper. vs. hypermethylated)	0.472 (0.276–0.806)	0.006

95% CI 95% confidence interval, CRC colorectal cancer, non-Hyper. non-hypermethylated
Italics values indicate statistically significant (P < 0.05)

ISSN: 1479-5876